EMA recommends authorisation of Rasonque for metastatic pancreatic cancer
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Rasonque (daraxonrasib), an oral treatment for adults with…
Résiliable à tout moment · 99 $ CA/mois


